Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-7762. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 known ✓ | O14757 | 18/20 | 1.00 |
| ▸ | MELK | Q14680 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-7762 SCHEMBL1127614 | 1.00 | CHEK1 (1.00) | CHEK1MELKPLK4GAKJAK2 | |
| Azd-7762 SCHEMBL1564574 | 1.00 | CHEK1 (1.00) | CHEK1MELKPLK4GAKJAK2 | |
| Azd-7762 SCHEMBL31517325 | 1.00 | CHEK1 (1.00) | CHEK1MELKPLK4GAKJAK2 | |
| Azd-7762 SCHEMBL15105420 | 1.00 | CHEK1 (1.00) | CHEK1MELKPLK4GAKJAK2 | |
| Azd-7762 SCHEMBL29994838 | 0.99 | MELK (1.00) | CHEK1MELKPLK4GAKJAK2 | |
| Azd-7762 SCHEMBL19457662 | 0.99 | MELK (1.00) | CHEK1MELKPLK4GAKJAK2 | |
| SCHEMBL31532638 | 0.97 | CHEK1 (0.95) | CHEK1MELKPLK4GAKJAK2 | |
| SCHEMBL31532541 | 0.97 | CHEK1 (0.95) | CHEK1MELKPLK4GAKJAK2 | |
| Azd-7762 SCHEMBL1127337 | 0.96 | CHEK1 (0.92) | CHEK1MELKPLK4GAKJAK2 | |
| SCHEMBL31532639 | 0.94 | CHEK1 (0.89) | CHEK1MELKPLK4GAKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025033367-A1 | COMBINATION THERAPY FOR ANTITUMOR AGENT | 湧永製薬株式会社 | 2025-02-13 | — | — | WO | claimed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | claimed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | claimed |
| WO-2026102277-A1 | COMBINATION THERAPIES COMPRISING IKZF2 DEGRADER COMPOUNDS | Plexium, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12473273-B2 | Quinoline compounds and compositions for inhibiting EZH2 | NOVARTIS AG (CH) | 2025-11-18 | — | — | US | disclosed |
| CN-119431341-A | Compounds and compositions for inhibiting EZH2 | 诺华公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2025033367-A1 | COMBINATION THERAPY FOR ANTITUMOR AGENT | 湧永製薬株式会社 | 2025-02-13 | — | — | WO | disclosed |
| CN-112261970-B | 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family zinc finger 2 (IKZF 2) dependent diseases | 诺华股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-116134027-B | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119301125-A | Crystalline forms of AKR1C3 dependent KARS inhibitors | 诺华股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119241499-A | 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-115052662-A | Use of anti-TGF-beta antibodies and checkpoint inhibitors for treating proliferative diseases | 诺华股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-4041725-A1 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| EP-4034535-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| CN-114746414-A | Aza-quinoline compounds and uses thereof | 诺华公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-4007592-A1 | ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF CANCER | LanthioPep B.V. (NL) | 2022-06-08 | — | — | EP | disclosed |
| CN-114514032-A | Angiotensin type 2 (AT2) receptor agonists for the treatment of cancer | 兰提欧派普有限公司 | 2022-05-17 | — | — | CN | disclosed |
| WO-2022043558-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043556-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022033492-A1 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | NOVARTIS AG (CH) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473273-B2 | Quinoline compounds and compositions for inhibiting EZH2 | EZH2, BMI1, SUZ12 | CHEK1 2712/4885MELK 218/4885PLK4 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.